Abstract
Patients with hypertension are at increased risk for SARS-CoV-2. There is an unconfirmed hypothesis that drugs for the treatment of hypertension – ACE inhibitors and ARBs – may cause complications in these patients. According to the latest data, possible alternative approach is switching to the potassiumsparing diuretic spironolactone due to its slightly different mechanism of action, which also has a favorable safety profile and benefit/risk ratio.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
